Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -55.32% is 11% below its 5-year average of -49.95%, around the middle of its 5-year range (-69.13%–-32.02%).
17.12% above its 12-month average of -66.75%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.76%.
RETURN ON ASSETS (ROA)
-55.32%
RETURN ON ASSETS (ROA) AVG TTM
-66.75%
RETURN ON ASSETS (ROA) AVG 3Y
-58.76%
RETURN ON ASSETS (ROA) AVG 5Y
-49.95%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.12%
CURRENT VS 3Y AVG
+5.85%
CURRENT VS 5Y AVG
-10.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-71.59%
vs the sector median at left
Hyperfine, Inc.
Market Cap
$73.86M
Return on Assets (ROA)
-55.32%
TTM Avg
-66.75%
3Y Avg
-58.76%
5Y Avg
-49.95%
Market Cap
$73.10M
Return on Assets (ROA)
-86.58%
TTM Avg
-89.71%
3Y Avg
-79.07%
5Y Avg
-70.23%
Market Cap
$74.90M
Return on Assets (ROA)
-41.94%
TTM Avg
-38.20%
3Y Avg
-35.26%
5Y Avg
-28.99%
Market Cap
$72.60M
Return on Assets (ROA)
-99.89%
TTM Avg
-66.19%
3Y Avg
-52.51%
5Y Avg
-39.81%
Market Cap
$75.82M
Return on Assets (ROA)
-5.84%
TTM Avg
-3.07%
3Y Avg
-3.13%
5Y Avg
-9.45%
Market Cap
$75.98M
Return on Assets (ROA)
-902.18%
TTM Avg
-2200.93%
3Y Avg
-2200.93%
5Y Avg
-2200.93%
Market Cap
$70.59M
Return on Assets (ROA)
-130.37%
TTM Avg
-128.36%
3Y Avg
-112.34%
5Y Avg
-87.04%
Market Cap
$76.75M
Return on Assets (ROA)
-30.65%
TTM Avg
-38.63%
3Y Avg
-43.27%
5Y Avg
-38.60%
Market Cap
$77.72M
Return on Assets (ROA)
-38.31%
TTM Avg
-38.33%
3Y Avg
-38.15%
5Y Avg
-51.76%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hyperfine, Inc. (HYPR) | $73.86M | -55.32% | -66.75% | -58.76% | -49.95% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $73.10M | -86.58% | -89.71% | -79.07% | -70.23% |
| Pulmonx Corporation (LUNG)vs › | $74.90M | -41.94% | -38.20% | -35.26% | -28.99% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.60M | -99.89% | -66.19% | -52.51% | -39.81% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.82M | -5.84% | -3.07% | -3.13% | -9.45% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $75.98M | -902.18% | -2200.93% | -2200.93% | -2200.93% |
| Gain Therapeutics, Inc. (GANX)vs › | $70.59M | -130.37% | -128.36% | -112.34% | -87.04% |
| Outset Medical, Inc. (OM)vs › | $76.75M | -30.65% | -38.63% | -43.27% | -38.60% |
| Sera Prognostics, Inc. (SERA)vs › | $77.72M | -38.31% | -38.33% | -38.15% | -51.76% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.73M | -136.52% | -104.53% | -92.09% | -76.74% |
ROA
-55.3%
ROE
-94.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -64.37% |
| 2024-12-31 | -69.13% |
| 2023-12-31 | -46.96% |
| 2022-12-31 | -54.58% |
| 2021-12-31 | -32.02% |
| 2020-12-31 | -32.66% |
| 2019-12-31 | -61.45% |
